Why Peptides Are Injected: Delivery Routes, Bioavailability, and What Survives Digestion

Most therapeutic peptides are administered subcutaneously because the digestive tract degrades them before they reach circulation. This article explains the pharmacology behind route selection, why oral and nasal peptide products behave differently, and what bioavailability actually means for a prescribed protocol.

By UAE Peptide Clinic Research Desk

One of the first questions patients ask is why peptide therapy involves a subcutaneous injection at all. If a peptide is simply a short chain of amino acids, and we eat protein every day, why can it not be taken as a capsule? The answer sits at the intersection of biochemistry and pharmacokinetics, and it explains most of what determines how a protocol is designed.

The digestive tract is built to destroy peptides

The gastrointestinal system exists to break dietary protein into individual amino acids. Gastric acid denatures peptide structure, while pepsin, trypsin, chymotrypsin and a family of brush-border peptidases cleave the peptide bonds that hold the molecule together. A therapeutic peptide swallowed in unprotected form is treated no differently from a mouthful of food.

Even a molecule that survives enzymatic degradation faces a second barrier. Peptides are relatively large and hydrophilic, which makes passive diffusion across the intestinal epithelium inefficient. Anything absorbed then passes through hepatic first-pass metabolism before reaching systemic circulation. Published estimates for unmodified oral peptide bioavailability typically sit below one to two per cent, and often far lower.

Route selection is not a matter of preference. It is a consequence of how a molecule behaves once it meets the body.

What subcutaneous administration solves

Injecting into the subcutaneous layer bypasses the gut and the liver entirely. The peptide is deposited into loose connective tissue with a modest blood supply, from which it is absorbed gradually into lymphatic and capillary circulation. This achieves two things at once: it protects the molecule, and it produces a smoother absorption curve than intravenous delivery, which tends to spike and clear quickly.

• Subcutaneous — the standard route for most prescribed peptides; predictable absorption, self-administered, well tolerated
• Intramuscular — faster absorption from a more vascular compartment; used selectively where a sharper onset is wanted
• Intravenous — immediate systemic availability, no absorption phase; reserved for clinic-administered infusions such as NAD+
• Topical — limited to peptides with local dermal targets, where systemic exposure is neither expected nor required
• Intranasal — the nasal mucosa offers direct access with partial avoidance of first-pass metabolism, but absorption is variable

Why some peptides do appear as sprays or capsules

A small number of peptides are formulated for non-injectable routes, and this is not marketing. Certain small, comparatively stable molecules studied in the nootropic literature have been investigated intranasally, where the mucosal route offers a shorter path to central circulation. Research has also produced orally viable peptide drugs through structural modification and permeation-enhancer technology, which is why an oral GLP-1 formulation exists at all. These are engineering achievements specific to individual molecules, not a general rule that can be applied across the peptide category.

The distinction matters commercially. Grey-market products marketed as oral versions of peptides that have only ever been studied by injection are unlikely to deliver a meaningful systemic dose. Absence of an injection is not evidence of a gentler product; it may simply be evidence of a product that does not reach the target tissue.

The clinical nuance: bioavailability sets the dose, not the other way round

When a prescriber writes a protocol, the stated dose is meaningful only in the context of route. The same quantity of peptide administered subcutaneously, intranasally or orally produces markedly different plasma exposure. This is why dosing data cannot be transferred between routes, why a preclinical study using intraperitoneal administration does not translate directly to a human subcutaneous protocol, and why comparing your regimen with someone else's without accounting for route is unhelpful. Route, dose, frequency and half-life are a single interdependent set of decisions.

What this means in practice

For most patients, subcutaneous administration remains the route with the strongest supporting evidence and the most predictable behaviour. Modern insulin-style needles are very fine, and once technique and site rotation are established, the majority of people find administration straightforward within the first week. The trade-off is a small procedural learning curve in exchange for confidence that the prescribed dose is genuinely reaching circulation.

If you are exploring peptide delivery routes as part of your protocol, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.